Angiocrine Bioscience
San Diego, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
JT
John T LomoroChief Financial Officer/Treasurer
PW
Paul W FinneganPresident/Chief Executive Officer
JR
John R JaskowiakChief Operating Officer/Secretary
MC
Marc CohenDirector
JJ
Jeff JonasDirector
DP
David ParkinsonDirector
JL
Jeffrey L PortDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$2.1MraisedSep 2025 · 16 investors · BiotechnologyRule 506(b)
▶$2.1MraisedSep 2025 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ParkinsonDirector
- Jeffrey L PortDirector
- John T LomoroExecutive Officer
- Paul W FinneganExecutive Officer, Director
- John R JaskowiakExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.1M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$58.1MraisedOct 2021 · 78 investors · BiotechnologyRule 506(b)
▶$58.1MraisedOct 2021 · 78 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc CohenDirector
- Jeff JonasDirector
- John JaskowiakExecutive Officer
- John LomoroExecutive Officer
- David ParkinsonDirector
- Paul FinneganExecutive Officer, Director
- Jeffrey PortDirector
- Offering amount
- $99.4M
- Amount sold
- $58.1M
- Sales commissions
- $4.4M
- Placement agents
- BOFA SECURITIES, INC.
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.